Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett Company, a manufacturer of generic pharmaceuticals, has received the FDA approval of its abbreviated new drug application for Ursodiol 300mg capsules, the generic equivalent of Actigall marketed by Watson Pharmaceuticals.
Subscribe to our email newsletter
Ursodiol is indicated for patients with radiolucent noncalcified gallbladder stones, and for the prevention of gallstone formation in obese patients experiencing rapid weight loss.
Arthur Bedrosian, president and CEO of Lannett, said: “The approval of Ursodiol expands our product offering and adds to the significant number of product approvals Lannett has received thus far in 2008.
“We continue to build a robust, diversified pipeline and remain optimistic that our growth strategy will continue to pay dividends. Our accomplishments this year are the result of the hard work and dedication of our employees.”